For the latest news on research in English please go to www.nationalmssociety.org or www.msif.org 2009 In this study using triple label enzyme immuno-histochemistry they showed that in all MS samples examined blood vessel density increased compared with controls. These findings suggest that angiogenesis may play a role in lesion progression, failure of repair and scar formation. Neurosci Lett. 2009 Dec 24 Patients receiving continuous fingolimod (FTY720) oral treatment had sustained low annualized relapse rates of 0.20-0.21, and 68-73% remained relapse-free at month 36 over 36 months. www.nationalmssociety.org/news/news-detail/index.aspx?nid=2154 The press release of the preliminary reports of Phase II of ocrelizumab showed a strong effect with a highly statistically significant reduction in signs of disease activity. The companies are continuing to analyze the data, and additional research will be needed to further determine this drug’s safety and benefits. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2447 Visual evoked potentials obtained in patients with multiple sclerosis using low-contrast stimuli are increased in latency or absent when compared with those obtained using high-contrast stimuli and, thus, may prove to be helpful in identifying demyelinating optic neuropathy. Neurology. 2009 Dec 1; 73(22):1849-57 Fatigue and poorer quality of life is a clear concern in pediatric MS, and is related to overall physical disability. Mult Scler. 2009 Nov 13 Cognitive impairment in Bening MS is associated with the extent of Corpus Collasum damage by MRI assessment. Hum Brain Mapp. 2008 Dec 9. [Epub ahead of print] Levetiracetam did not affect tremor severity or functionality in patients with MS http://msj.sagepub.com/cgi/content/abstract/1352458508099142v1 Preliminary studies on the effect of levetiracetam on chronic pain in MS suggest further studies needed to confirm efficacy. http://www3.interscience.wiley.com/journal/121640026/abstract MRI measures widely used in trials of relapsing-remitting and progressive multiple sclerosis add little if anything independently to the clinically relevant relapse and disability outcomes. Neurology. 2008 Dec 10 (Publicado en la internet antes de imprimir) 2008 Cannabis Use Worsens Cognitive Function in MS Patients Published on Neurology 2008; 71: 164- 169. http://www.medscape.com/viewarticle/578376 Verbal Memory decline evolves independently of disease activity in MS. Multiple Sclerosis, Vol. 14, No. 7, 947-953 http://msj.sagepub.com/cgi/content/abstract/14/7/947 Even though MS in North African migrants in France has an earlier onset, progresses rapidly, start t earlier treatment prescription and use more frequently immune-suppressors, this new data shows that patients appear as responsive as other MS patients to DMD treatment. Multiple Sclerosis, Vol. 14, No. 7, 933-939 (2008). http://msj.sagepub.com/cgi/content/abstract/14/7/933 MS patients do not generally have peripheral nerve demyelination, but approximately 5% of patients develop demyelinating neuropathy. Clin Neurophysiol. 2008 Aug; 119 (8):1829-33. Epub 2008 May 20. http://www.ncbi.nlm.nih.gov/pubmed/18495530?ordinalpos=3&itool=EntrezSystem2. PEntr This phase 2 study suggests that a subgroup of patients, when treated with fampridine, experiences a clinically relevant improvement in walking ability, which is sustained for at least 14 weeks. http://www.neurology.org/cgi/content/abstract/01.wnl.0000326213.89576.0ev1 Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol. 2008 Jul;15(7):677-80. Epub 2008 May 6 http://www.ncbi. nlm.nih.gov/pubmed/18459972?ordinalpos=4&itool=EntrezSystem2.PEntr Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/17944900?ordinalpos=1&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Evidence of thalamic gray matter loss in pediatric multiple sclerosis http://www.neurology.org/cgi/content/abstract/01.wnl.0000291010.54692.85v1 Integrating risk factors. HLA-DRB1*1501 and Epstein-Barr virus in multiple http://www.neurology.org/cgi/content/abstract/01.wnl.0000294325.63006.f8v1 Teva reports that patients who switched from interferon beta (IFN beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in annualized relapse rates (0.63 to 0.14). In addition, these patients did not progress significantly in their disability as measured by expanded disability status scale (EDSS). http://www.pharmaceutical-business-review.com/article_news.asp?guid=1278A412-15D0-4D6A- B050-35C6EA43A476 Biopharmaceutical company MediciNova Inc. (MNOV) announced positive clinical results for the two year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis. The trial reported slowing of disability progression and significant neuroprotective effects. http://www.rttnews.com/sp/breakingnews.asp?date=04/07/2008&item=35&vid=0 Open label study of Campath-1-H showed that it is very effective at preventing relapses in the small minority of patients with relapsing-remitting MS who have early aggressive disease. However there was a higher risk of side effects than with conventional treatments. http://www.ncbi.nlm.nih gov/pubmed/18283404?ordinalpos=1&itool=EntrezSystem2.PEntrez. Pubmed Pubmed_ResultsPanel.Pubmed_RVDocSum Open label study looked at mitoxantrone and cyclophosphamide in patients with severe relapsing remitting MS not responding to standard therapy, and in worsening secondary progressive MS. They found that both drugs reduced MRI activity, and disease progression was slightly slower in the mitoxantrone group. Side effects were more problematic in the cyclophosphamide group. http://www.ncbi.nlm.nih.gov/pubmed/17870094?ordinalpos=2&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum They found that having a baby after MS was diagnosed was associated with lower birth weights, but that did not have any negative effects on the babies, in terms of numbers of complications or interventions. http://www.ncbi.nlm.nih.gov/pubmed/18283397?ordinalpos=1&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum A single course of rituximab treatment reduced the number of brain lesions and clinical relapses in a 48-week, phase II trial of 104 patients with relapsing-remitting multiple sclerosis (MS). N Engl J Med 2008;358:676-688. http://www.ncbi.nlm.nih.gov/pubmed/18272891?ordinalpos=1&itool=EntrezSystem2.PEntrez. Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Note: MSIF related links may have been removed from the host website. We apologized for the inconvenience. 2007 Vaccinating against the hepatitis B virus does not appear to be associated with the risk of developing multiple sclerosis in childhood, according to study done in France. Arch Pediatr Adolesc Med. 2007;161(12):1176-1182] www.jamamedia.org. BioMS Medical Corp. announced that the company has received a recommendation from an independent Data Safety Monitoring Board to continue MAESTRO-01, its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. MBP8298 is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein that is administer intravenously. http://www.biomsmedical.com/product_overview.asp Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage and should be consider as symptomatic. Higher disability and cervical cord damage represent a significant risk factor for RLS in MS patients. [Multiple Sclerosis 2008;14: 86—93]. http://msj.sagepub.com/cgi/content/abstract/14/1/86 A study reports that HLA-DRB1 *01 acts as an independent modifier the disease progression. This allele appears to attenuate the progressive disability that characterizes MS in the long term. The observation was doubly replicated in a Sardinian benign and malignant patients and a cohort of affected sibling pairs discordant for HLA-DRB1 *01 . http://www.pnas.org/cgi/content/abstract/104/52/20896 Scientists based at Jerusalem's Hadassah University Hospital have broken new ground in the field of stem cell research by injecting 26 multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) patients. with therapeutic quantities of cultured adult stem cells harvested from their own hip marrow. After extraction, the cells were subjected to an in vitro cleansing, multiplication and chemical 'tagging', being re-injected into the patients via lumbar puncture. The trials were the first in the world to use this type of stem cells. No adverse effects were noted, and the patients displayed anecdotal improvements in clinical symptoms, leading the way for further developments in forthcoming clinical trials. This result is considered highly experimental since it lacks a control group. http://www.israel21c.org/bin/en.jsp?enDispWho=Articles% 5El1889&enSearchQueryID=48&enPage=BlankPage&enDisplay=view&enDispWhat=object&enVers ion=0&enZone=Health& A study found that this new MRI techinique using high-field proton magnetic resonance spectroscopy in patients with clinically isolated syndromes can be use as a predictive tool of who would go on to develop MS. [Neuroradiology. 2007 Nov 3] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17982745&ordinalpos=1&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum BRIGHT study reported that Patients with relapsing-remitting multiple sclerosis (MS) treated with 250 mcg Betaseron (interferon beta-1b) experienced less injection site pain and fewer injection site reactions than those treated with 44 mcg Rebif. The BRIGHT study is a multicenter (76 centers), international (13 countries), non-randomized, prospective, observational study comparing the tolerability of Betaseron with Rebif with 454 patients. [Bayer HealthCare Pharmaceuticals PressRelease in earthtimes.org] http://www.earthtimes.org/articles/show/news_press_release,217975.shtml The authors explain a possible role of Epstein-Barr virus infection in multiple sclerosis. [J Exp Med. 2007 Nov 5] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17984305&ordinalpos=1&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum The role of optical coherence tomography (OCT) in multiple sclerosis was examined by an expert panel consensus that concluded the technique may be very useful in future trials. [J Neurol Sci. 2007 Dec 15;263(1-2):3-14. Epub 2007 Jul 27]. http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17673257&ordinalpos=4&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Researchers found that a year after a community-based course to teach effective method of managing fatigue in MS had terminated, the techniques learned were still effective in managing the fatigue. [Int J Rehabil Res. 2007 Dec;30(4):305-313] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17975450&ordinalpos=1&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Eye Scanning Device Detects MS Nervous System Damage National MS Society Research update http://www.nationalmssociety.org/site/PageServer? pagename=HOM_RES_research_2007oct18 In an Italian study, vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. [Multiple Sclerosis, Vol. 13, No. 9, 1200-1202 (2007)] http://msj.sagepub.com/cgi/content/abstract/13/9/1200 Large scale study was unable to show superiority of Betaferon 500 mcg compared to Betaferon 250 mcg and Copaxone. Betaferon 250 mcg is still the optimal Betaferon dose based on high efficacy and excellent tolerability. http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx_ttnews%5btt_news% 5d=12123&tx_ttnews%5bbackPid%5d=36&cHash=5e8c70c707 The U.S. Food and Drug Administration (FDA) has issued a warning in connection with the drug Provigil because of dangerous side effects; among those found are Stevens-Johnson Syndrome (red rash), hallucinations, anxiety and suicidal thoughts. FDA recomends to talk and see to your doctor regarding this news. http://www.news-medical.net/?id=31791 Survey found that although no differences were noted in terms of disease severity and diagnostic history, findings indicated that people treated at MS Comprehensive Care Centers had better access to health care services and perceived their health care experiences more positively than those who never received MS care from a Comprehensive Care Centers. http://www.mscare. org/cmsc/Current-Issue.html A study wants to establish a test battery that could be used as an outcome to succinctly and sufficiently measure fatigue in MS patients with mild to moderate disability. [International Journal MS Care. 2007;9:118–125] http://www.mscare.org/cmsc/Current-Issue.html Analysis showed that compared to patients with no family history of MS, familial MS patients had significantly more destructed lesions, and significantly lower volume of whole brain, white matter and gray matter, as well as other indications of greater brain degradation. http://www.medindia.net/news/MS-That-Runs-In-Families-Appears-More-Severe-Than-Non-Familial- MS-27655-2.htm Sirtris pharmaceuticals' oral drug SRT501 shown to be neuroprotective in laboratory animals with a model of optic neuritis. http://www.genengnews.com/news/bnitem.aspx?name=24426455 Recent studies have indicated that brain atrophy is more closely associated with cognitive impairment in MS than conventional MRI lesion measures. http://www.msif.org/en/global_ms_network/ms_news/ms_and_cognition.html Cannabis (marihuana) use was linked to an increase risk of psychosis in later life. (pdf format) http://www.medscape.com/viewarticle/560746?src=mp A study examines the variability of cannabis to treat effectively pain in people with MS. They will try to explain pharmacologically that the reason for this variation is due to the pathogenesis of the pain and the receptors involve. [European Journal of Neurology 14 (10), 1162–1169] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2007.01903.x Genetics. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. [Int Rev Neurobiol. 2007;79:521-35] http://www.ncbi.nlm.nih.gov/sites/entrez? db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17531857&query_hl=15&itool=pubmed_ docsum The Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score is used as an early prediction of long term evolution of MS. It may be useful both to identify patients who are candidates for early or for more aggressive therapies and to improve the design and analysis of clinical therapeutic trials and of observational studies. [J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):757-9. Epub 2007 Jan 12] http://www.ncbi.nlm.nih.gov/sites/entrez? Db=pubmed&Cmd=ShowDetailView&TermToSearch=17220286&ordinalpos=9&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum The Latin American Association for MS has a new website.http://www.ulasem.org Retinal nerve fiber layer atrophy and retinal periphlebitis are associated with disease activity, that includes new relapses and disability. [NEUROLOGY 2007;68:1488-1494] http://www.neurology.org/cgi/content/abstract/68/18/1488 Interferon-beta therapy may reduce MS activity by suppression or depletion of autoreactive, pro inflammatory T-cells. http://www.msif.org/en/research/research_news/reduces_cd4_and.html Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.[NEUROLOGY 2007;68: 1299-1304] http://www.neurology.org/cgi/content/abstract/68/16/1299 A study finds high prevalence of restless legs syndrome in multiple sclerosis. Restless leg syndrome is also associated with higher disability. [European Journal of Neurology 14 (5), 534–539] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2007.01740.x Clinical trial of cannabis-based medicine may be useful for treatment of spasticity in MS.[European Journal of Neurology 14 (3), 290–296] http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2006.01639.x? journalCode=ene&volume=14&issue=3 Randomized double-blind, dose comparison study of glatiramer acetate in relapsing-remitting MS shows that a dose of 40 mg was safe, well tolerated and may be more effective than the currently approved 20mg daily dose in reducing MRI activity and clinical relapses.[NEUROLOGY 2007;68:939- 944] http://www.neurology.org/cgi/content/abstract/68/12/939 Age at onset determines the occurrence of the progressive phase of multiple sclerosis. http://www.neurology.org/cgi/content/abstract/68/10/779 |
Maria A Reyes-Velarde, MD, MPH hablemosdeeem.com |
Latest News
Disclaimer:
WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIFFICULTY IN USE,
INACCURACY OR INCOMPLETENESS OF INFORMATION, USE OF THIS INFORMATION OR RESULTS
ARISING FORM THE USE OF IT, COMPUTER VIRUSES, MALICIOUS CODE, LOSS OF DATA,
COMPATIBILITY ISSUES, OR OTHERWISE. WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY
FOR ANY DIRECT, INDIRECT, SPECIAL INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE
DAMAGES (INCLUDING LOST PROFITS, LOST DATA. COST TO PROCURE REPLACEMENT SERVICES
OR GOODS, OR BUSINESS OPPORTUNITIES) ARISING OUT OF YOUR ACCESS TO OR USE OF OUR
SITE, OR ANY OTHER LINK WE PROVIDE TO ANOTHER SITE, OR ANY ACTS, OMISSIONS, DEFECTS,
SECURITY BREACHES, OR DELAYS, REGARDLESS OF THE BASIS OF THE CLAIM OR IF WE HAVE BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGE OR LOSS. EACH PERSON HAS TO CONSULT ANY
INFORMATION WITH HIS/HER PHYSICIAN.
WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIFFICULTY IN USE,
INACCURACY OR INCOMPLETENESS OF INFORMATION, USE OF THIS INFORMATION OR RESULTS
ARISING FORM THE USE OF IT, COMPUTER VIRUSES, MALICIOUS CODE, LOSS OF DATA,
COMPATIBILITY ISSUES, OR OTHERWISE. WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY
FOR ANY DIRECT, INDIRECT, SPECIAL INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE
DAMAGES (INCLUDING LOST PROFITS, LOST DATA. COST TO PROCURE REPLACEMENT SERVICES
OR GOODS, OR BUSINESS OPPORTUNITIES) ARISING OUT OF YOUR ACCESS TO OR USE OF OUR
SITE, OR ANY OTHER LINK WE PROVIDE TO ANOTHER SITE, OR ANY ACTS, OMISSIONS, DEFECTS,
SECURITY BREACHES, OR DELAYS, REGARDLESS OF THE BASIS OF THE CLAIM OR IF WE HAVE BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGE OR LOSS. EACH PERSON HAS TO CONSULT ANY
INFORMATION WITH HIS/HER PHYSICIAN.
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
©2001-2010 maria a.
reyes-velarde
Permission to use/copy any
part of the site "HABLEMOS DE
ESCLEROSIS MULTIPLE" must
be granted by the author
reyes-velarde
Permission to use/copy any
part of the site "HABLEMOS DE
ESCLEROSIS MULTIPLE" must
be granted by the author
ESCLEROSIS MULTIPLE
©2001-2010maria a. reyes-velarde
©2001-2010maria a. reyes-velarde